Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Catalent secures $700mm bridge loan commitment to support concurrent Cook Pharmica acquisition

Executive Summary

Catalent Inc., to help finance its concurrent $950mm buy of fellow CRO Cook Pharmica LLC, entered into a $700mm senior unsecured bridge loan facility commitment with Morgan Stanley, JP Morgan Chase, Royal Bank of Canada, RBC Capital Markets, Bank of America Merrill Lynch, and Merrill Lynch Pierce Fenner & Smith Inc. Catalent is also using cash on hand and proceeds from a concurrent public equity offering to fund the acquisition of Cook, and doesn’t expect to borrow under the facility, but it is there if it needs the extra money.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies